Perineural or intravenous dexamethasone for adductor canal and interspace block between the popliteal artery and posterior knee capsule blocks in total knee arthroplasty: a randomized trial
Pain Medicine · 19.10.2026
DOI: 10.1093/pm/pnag140 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, online erschienen am 19.10.2026. Verfasst von Tomasz Reysner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Poznan University of Medical Sciences, Department of Pediatric Anesthesiology and Intensive Care, Poznan, Poland. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Importance Total knee arthroplasty causes substantial postoperative pain. Combined adductor canal and interspace block between the popliteal artery and posterior knee capsule (iPACK) provides motor-sparing analgesia, but its duration is limited.
Objective
To compare perineural and intravenous dexamethasone as adjuncts to adductor canal and iPACK blocks in older patients undergoing primary total knee arthroplasty.
Design
Prospective, randomized, quadruple-blind, parallel-group trial.
Setting
Wiktor Dega Orthopaedic and Rehabilitation Clinical Hospital, Poznan University of Medical Sciences, a tertiary referral hospital in Poznan, Poland.
Participants
Ninety patients aged 65-100 years undergoing primary total knee arthroplasty. Intervention(s) or exposure(s) Patients were allocated equally to receive adductor canal and iPACK blocks with ropivacaine plus perineural dexamethasone 4 mg in total (2 mg per block), intravenous dexamethasone 4 mg, or placebo. Main outcome(s) and measure(s) The primary outcome was time to first rescue opioid analgesia within 48 h. Secondary outcomes included opioid consumption, pain scores, inflammatory markers, blood glucose, quadriceps strength, and neurological safety.
Results
Time to first rescue opioid analgesia differed between groups (log-rank P < .001). Median time (95% CI) was 4.5 (4.5-5.5) h with placebo, 13.9 (12.5-14.7) h with intravenous dexamethasone, and 18.5 [16.5 to not reached (NR)] h with perineural dexamethasone. The proportions remaining opioid-free at 48 h were 0%, 23.3%, and 36.7%, respectively. Opioid consumption and pain scores were lower with both dexamethasone routes than with placebo; perineural administration resulted in the lowest opioid consumption and lower pain scores than intravenous administration at later timepoints. Perineural dexamethasone was associated with lower postoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, whereas intravenous dexamethasone was associated with higher blood glucose. No motor weakness or nerve injury occurred. Conclusions and relevance Perineural dexamethasone prolonged analgesia and reduced opioid requirements more than intravenous dexamethasone, without neurological or motor impairment. The inflammatory-marker findings were exploratory and do not establish independent clinical benefit. Clinical trial registration This trial was registered at ClinicalTrials.gov (NCT07180953). The record was released for review through the ClinicalTrials.gov Protocol Registration and Results System on September 12, 2025, before enrollment of the first participant on September 13, 2025, and was first publicly posted on September 17, 2025 following registry review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Poznan University of Medical Sciences, Department of Pediatric Anesthesiology and Intensive Care, Poznan, Poland.
- Poznan University of Medical Sciences, . Department of Anesthesiology and Intensive Care, ; Poznan, Poland.
- Poznan University of Medical Sciences, ; Department of Palliative Medicine, Poznan, Poland.
- Poznan University of Medical Sciences, ; Department of Pathophysiology of Locomotor Organs, Poznan, Poland.
- Poznan University of Medical Sciences, Department of Clinical Anesthesiology and Pain Management, Poznan, Poland.
ORCID-Profile: Tomasz Reysner, Alicja Bartkowska-Śniatkowska, Jowita Rosada-Kurasińska, Katarzyna Wieczorowska-Tobis, Przemysław Daroszewski, Malgorzata Reysner
Zitieren
APA
Reysner, T., Bartkowska-Śniatkowska, A., Rosada-Kurasińska, J., Wieczorowska-Tobis, K., Daroszewski, P., & Reysner, M. (2026). Perineural or intravenous dexamethasone for adductor canal and interspace block between the popliteal artery and posterior knee capsule blocks in total knee arthroplasty: a randomized trial. Pain Medicine. https://doi.org/10.1093/pm/pnag140
Vancouver
Reysner T, Bartkowska-Śniatkowska A, Rosada-Kurasińska J, Wieczorowska-Tobis K, Daroszewski P, Reysner M. Perineural or intravenous dexamethasone for adductor canal and interspace block between the popliteal artery and posterior knee capsule blocks in total knee arthroplasty: a randomized trial. Pain Medicine. 2026. doi:10.1093/pm/pnag140
BibTeX
@article{Reysner2026,
author = {Reysner, Tomasz and Bartkowska-Śniatkowska, Alicja and Rosada-Kurasińska, Jowita and Wieczorowska-Tobis, Katarzyna and Daroszewski, Przemysław and Reysner, Malgorzata},
title = {Perineural or intravenous dexamethasone for adductor canal and interspace block between the popliteal artery and posterior knee capsule blocks in total knee arthroplasty: a randomized trial},
journal = {Pain Medicine},
year = {2026},
doi = {10.1093/pm/pnag140}
}
EUVIMED